Evotec SE
XETRA:EVT
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
5.265
21.51
|
Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one EVT stock under the Base Case scenario is 12.69 EUR. Compared to the current market price of 8.5 EUR, Evotec SE is Undervalued by 33%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Evotec SE
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for EVT cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Evotec SE
Balance Sheet Decomposition
Evotec SE
Current Assets | 698.1m |
Cash & Short-Term Investments | 378.5m |
Receivables | 227.8m |
Other Current Assets | 91.8m |
Non-Current Assets | 1.3B |
Long-Term Investments | 123.5m |
PP&E | 813.8m |
Intangibles | 295.9m |
Other Non-Current Assets | 59.6m |
Current Liabilities | 333.6m |
Accounts Payable | 69.9m |
Other Current Liabilities | 263.7m |
Non-Current Liabilities | 688.7m |
Long-Term Debt | 416.5m |
Other Non-Current Liabilities | 272.2m |
Earnings Waterfall
Evotec SE
Revenue
|
777.1m
EUR
|
Cost of Revenue
|
-670.6m
EUR
|
Gross Profit
|
106.5m
EUR
|
Operating Expenses
|
-200.1m
EUR
|
Operating Income
|
-93.6m
EUR
|
Other Expenses
|
-77.8m
EUR
|
Net Income
|
-171.4m
EUR
|
Free Cash Flow Analysis
Evotec SE
EUR | |
Free Cash Flow | EUR |
In Q1 2024, Evotec reported EUR 208.8 million in revenue, a 2% decrease from the previous year, mainly due to a 23% decline in Shared R&D. However, Just - Evotec Biologics saw a revenue surge of over 380%, driven by collaborations with Sandoz and the Department of Defense. Despite pressures on gross margins and adjusted EBITDA falling by 73%, the company remains optimistic about recovery in H2 2024, aided by strong Discovery sales. Evotec maintains its guidance for mid-double-digit EBITDA growth, with future improvements expected from ongoing cost optimization and strategic partnerships.
What is Earnings Call?
EVT Profitability Score
Profitability Due Diligence
Evotec SE's profitability score is 32/100. The higher the profitability score, the more profitable the company is.
Score
Evotec SE's profitability score is 32/100. The higher the profitability score, the more profitable the company is.
EVT Solvency Score
Solvency Due Diligence
Evotec SE's solvency score is 40/100. The higher the solvency score, the more solvent the company is.
Score
Evotec SE's solvency score is 40/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
EVT Price Targets Summary
Evotec SE
According to Wall Street analysts, the average 1-year price target for EVT is 12.9 EUR with a low forecast of 4.04 EUR and a high forecast of 30.45 EUR.
Dividends
Current shareholder yield for EVT is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
EVT Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. The company is headquartered in Hamburg, Hamburg and currently employs 4,521 full-time employees. The firm is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Officers
The intrinsic value of one EVT stock under the Base Case scenario is 12.69 EUR.
Compared to the current market price of 8.5 EUR, Evotec SE is Undervalued by 33%.